<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00242619</url>
  </required_header>
  <id_info>
    <org_study_id>95552</org_study_id>
    <nct_id>NCT00242619</nct_id>
  </id_info>
  <brief_title>Insulin Resistance in Patients With Mood Disorder</brief_title>
  <official_title>Rosiglitazone Add-On in Treatment of Depressed Patients With Insulin Resistance: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin resistance is known to be associated with mood disorders and cognitive difficulties.
      The purpose of this study is to treat depressed patients with rosiglitazone (also known as
      [AKA] Avandia), therefore improving glucose sensitivity, which in turn has the potential to
      affect mood and thinking. We, the researchers at Stanford University, are recruiting men and
      women who have been diagnosed with depression, and are willing to participate in this 3 month
      study. Participation involves neuropsychological testing, 2 blood draws called an oral
      glucose tolerance test (OGTT), which tests for glucose and insulin levels, and the
      medication, rosiglitazone. Participants are allowed to continue on their current psychiatric
      medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An association between insulin resistance (IR) and affective disorders has been postulated in
      a number of cross-sectional studies. Limited data exist on potential changes in IR associated
      with improvement in depressive symptoms and/or depression remission resolution - two studies
      reported decreased IR after successful antidepressant treatment, while another study reported
      persisting IR even after successful treatment.

      We have postulated that IR is a part of the pathophysiology of affective disorders, and its
      improvement (via pharmacological or nonpharmacological treatments) may significantly reduce
      the severity of depressive symptoms. In support of this hypothesis, we previously reported
      increased IR in women with bipolar disorder, as well as a significant association between IR
      and depressive symptoms in women with primary IR syndrome (polycystic ovary syndrome [PCOS]).
      In the current pilot study, we attempted a more direct testing of the hypothesis that
      improvement of IR will result in improvement in mood in patients with depressive disorders.
      The aim of the study was to evaluate whether addition of the peroxisome
      proliferator-activated receptor-γ (PPAR) agonist rosiglitazone to the treatment as usual
      (TAU) of nondiabetic patients with unipolar or bipolar depression would result in improvement
      in depression severity and clinical global impression (CGI). Insulin sensitizing agents have
      proven efficacious in nondiabetic IR, or &quot;prediabetic&quot;, individuals. All subjects in this
      pilot study had elevated fasting plasma glucose (FPG) and ratios of high density lipoproteins
      (HDL) to triglycerides (TG), which are established surrogate markers of IR.

      In the current pilot study, we attempted a more direct testing of the hypothesis that
      improvement of IR will result in improvement in mood in patients with depressive disorders.
      The aim of the study was to evaluate whether addition of the peroxisome
      proliferator-activated receptor-γ (PPAR) agonist rosiglitazone to the treatment as usual
      (TAU) of nondiabetic patients with unipolar or bipolar depression would result in improvement
      in depression severity and clinical global impression (CGI). Insulin sensitizing agents have
      proven efficacious in nondiabetic IR, or &quot;prediabetic&quot;, individuals. All subjects in this
      pilot study had elevated fasting plasma glucose (FPG) and ratios of high density lipoproteins
      (HDL) to triglycerides (TG), which are established surrogate markers of IR.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HDRS-21)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Hamilton Depression Rating Scale (HDRS-21) measures depression severity on a scale from 0 to 21, with 0 being the lowest level of depression severity and 21 being the highest level of depression severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression-Severity Scale (CGI-S)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Clinical Global Impression-Severity Scale (CGI-S) assesses depression severity. It is a 7-point scale, where 1 is the lowest level of depression severity and 7 is the highest level of depression severity.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Depression</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Rosiglitzone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group includes all 12 subjects who received rosiglitazone. Rosiglitazone was administered in addition to current antidepressant and/or mood-stabilizing medication at a dose of 4 mg/day for the first 4 weeks, with subsequent increase in dose to 9 mg/day for the remaining 8 weeks of the 12-week trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone</intervention_name>
    <description>Rosiglitazone was administered at two different doses over the 12-week period.</description>
    <arm_group_label>Rosiglitzone</arm_group_label>
    <other_name>Avandia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:- Current depression

          -  Insulin resistance

          -  Current physician/psychiatrist care

          -  Between the ages of 18-60

          -  Willing to sign the Human Subjects Protection Consent Form

          -  Willing to have blood sampling

        Exclusion Criteria:- Diabetes

          -  History of unstable heat disease

          -  Uncontrolled hypertension

          -  Extensive use of alcohol

          -  Current use of street drugs

          -  History of myocardial infarction

          -  History of cerebrovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Natalie Rasgon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://bne.stanford.edu/</url>
    <description>Stanford University Behavioral Neuroendocrinology Program</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2005</study_first_submitted>
  <study_first_submitted_qc>October 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2005</study_first_posted>
  <results_first_submitted>October 10, 2016</results_first_submitted>
  <results_first_submitted_qc>December 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 14, 2017</results_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Natalie Rasgon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Completers</title>
          <description>Subjects who completed the study and 12 weeks of taking rosiglitazone.</description>
        </group>
        <group group_id="P2">
          <title>Drop-Outs</title>
          <description>Subjects who dropped out and did not complete the 12 weeks on rosiglitazone.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Completers</title>
          <description>Subjects who met all criteria, took rosiglitazone, and completed the study.</description>
        </group>
        <group group_id="B2">
          <title>Drop-Outs</title>
          <description>Subjects who met all criteria, took rosiglitazone, and did not complete the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.9" spread="5.6"/>
                    <measurement group_id="B2" value="52.0" spread="6.5"/>
                    <measurement group_id="B3" value="51.95" spread="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Depression Rating Scale (HDRS-21)</title>
        <description>The Hamilton Depression Rating Scale (HDRS-21) measures depression severity on a scale from 0 to 21, with 0 being the lowest level of depression severity and 21 being the highest level of depression severity.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Completers</title>
            <description>Subjects who completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Drop-Outs</title>
            <description>Subjects who dropped out of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale (HDRS-21)</title>
          <description>The Hamilton Depression Rating Scale (HDRS-21) measures depression severity on a scale from 0 to 21, with 0 being the lowest level of depression severity and 21 being the highest level of depression severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="5.0"/>
                    <measurement group_id="O2" value="13.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Global Impression-Severity Scale (CGI-S)</title>
        <description>The Clinical Global Impression-Severity Scale (CGI-S) assesses depression severity. It is a 7-point scale, where 1 is the lowest level of depression severity and 7 is the highest level of depression severity.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Completers</title>
            <description>Subjects who completed the study and 12 weeks of taking rosiglitazone.</description>
          </group>
          <group group_id="O2">
            <title>Drop-Outs</title>
            <description>Subjects who dropped out and did not complete the 12 weeks on rosiglitazone.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression-Severity Scale (CGI-S)</title>
          <description>The Clinical Global Impression-Severity Scale (CGI-S) assesses depression severity. It is a 7-point scale, where 1 is the lowest level of depression severity and 7 is the highest level of depression severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0.6"/>
                    <measurement group_id="O2" value="3.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over 12 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Completers</title>
          <description>Subjects who met all criteria, took rosiglitazone, and completed the study.</description>
        </group>
        <group group_id="E2">
          <title>Drop-Outs</title>
          <description>Subjects who met all criteria, took rosiglitazone, and did not complete the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Natalie Rasgon</name_or_title>
      <organization>Stanford University</organization>
      <phone>(650) 724-6689</phone>
      <email>natalie.rasgon@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

